Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Al B. Benson, Michael I. D’Angelica, Thomas A. Abrams, Aijaz Ahmed, Mehmet Akce, Daniel A. Anaya, Robert A. Anders, Chandrakanth Are, Lydia Aye, Melinda Bachini, Marshall S. Baker, David C. Binder, Daniel B. Brown, Adam M. Burgoyne, Jason Castellanos, Jordan M. Cloyd, Darren R. Cullinan, Joseph W. Franses, Evan S. Glazer, William P. Harris, Renuka Iyer, Lawrence J. Jennings, Robin Kate Kelley, Sajid Khan, Matthew H. Levine, Laleh G. Melstrom, Manisha Palta, Steven S. Raman, Sean M. Ronnekleiv‐Kelly, Vaibhav Sahai, Stacey Stein, Kevin L. Stephans, Kannan Thanikachalam, Anita Turk, Jean‐Nicolas Vauthey, Alan P. Venook, Motoyo Yano, Adam C. Yopp, Ken Zhao, Ryan Schonfeld, Cindy Hochstetler
Abstract
The NCCN Guidelines for Biliary Tract Cancers (BTCs) provide recommendations for the evaluation and comprehensive care of patients with gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. The multidisciplinary panel of experts is convened at least once annually to review requests from internal and external entities as well as to evaluate new data on current and emerging therapies. This manuscript focuses on the adjuvant chemotherapy and chemoradiation treatment options for BTCs as well as the systemic treatment recommendations for patients with advanced BTCs.